Clinical Trial

Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Name: Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma — clinical trial record (NCT07689175)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.

Trial Details

NCT Number	NCT07689175
Lead Sponsor	University of Texas Southwestern Medical Center Collaborators: National Cancer Institute (NCI)
Conditions	Hepatocellular Carcinoma (HCC)
Enrollment	60 participants
Start Date	2026-10-31
Primary Completion	2031-10-31 (estimated)
Study Completion	2032-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-08